Financial Data and Key Metrics Changes - The reported revenue for Q4 2025 was $29.5 million, a 19% increase from $24.7 million in Q4 2024 [10] - Gross profit for Q4 2025 was $18.7 million, up 20% from $15.5 million in Q4 2024, with gross margins increasing to 63.2% from 62.7% [11] - The operating loss for Q4 2025 increased by 14% to $5.3 million compared to $4.6 million in Q4 2024 [11] - Net loss rose 31% to $8.9 million from $6.8 million in the prior year, driven by increased financial expenses [12] - Adjusted EBITDA for Q4 was -$2.1 million, compared to -$1.4 million in Q4 2024 [12] - Cash and cash equivalents as of December 31, 2025, were $29 million [12] Business Line Data and Key Metrics Changes - Total billable volume in Q4 was approximately 38,000 tests, with tissue-based tests decreasing by 5% and liquid-based tests increasing by 128% year-over-year [10] - The acquisition of ExoDx contributed to the growth in liquid-based tests, which include Select mdx, Resolve mdx, and ExoDx [10][34] Market Data and Key Metrics Changes - The company aims to balance revenue contributions from tissue and liquid tests, which previously saw tissue tests accounting for 85% of revenue [34] - The integration of ExoDx is expected to enhance the customer base and drive growth in both segments [34] Company Strategy and Development Direction - MDxHealth's strategy focuses on menu expansion, operational discipline, and customer experience, which are expected to drive sustained top-line growth [4][6] - The company is committed to integrating ExoDx and enhancing its sales organization to capitalize on the combined customer base [34] - The goal for 2026 is to achieve revenue guidance of $137 million to $140 million, reflecting a 28% year-over-year growth [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver growth and profitability, emphasizing the importance of operational discipline and customer experience [3][14] - The integration of ExoDx is seen as a significant growth opportunity, with expectations for improved operational efficiencies and market leadership in prostate cancer diagnostics [6][16] Other Important Information - The company amended its earn-out payment to Exact Sciences, reducing the upcoming payment by nearly $20 million, providing additional financial flexibility [8] - The collaboration with the University of Oxford is expected to enhance the utility of the GPS test in clinical guidelines, further solidifying MDxHealth's market position [16] Q&A Session Summary Question: Tissue ASP decline and mix shift - Management confirmed that the decline in tissue ASP was due to a mix shift towards Confirm and noted that ASPs reflect Medicare rates [19] Question: EBITDA performance and cash flow - Management acknowledged the lower EBITDA and higher cash burn, attributing it to the integration of ExoDx and expressed confidence in achieving a 10% EBITDA margin by year-end [20][21] Question: 2026 revenue guidance assumptions - Management indicated that the guidance reflects balanced growth from both tissue and liquid segments, with significant contributions expected from the ExoDx acquisition [32][34] Question: Operating leverage and gross margin expectations - Management stated that they expect to maintain flat OpEx while achieving growth and indicated that gross margins are expected to remain in the low 60s, with aspirations for improvement [44][46]

Financial Data and Key Metrics Changes - The reported revenue for Q4 2025 was $29.5 million, a 19% increase from $24.7 million in Q4 2024 [17] - Gross profit for Q4 2025 was $18.7 million, up 20% from $15.5 million in Q4 2024, with gross margins increasing to 63.2% from 62.7% [18] - The operating loss for Q4 2025 increased by 14% to $5.3 million compared to $4.6 million in Q4 2024 [18] - The net loss for Q4 2025 rose by 31% to $8.9 million from $6.8 million in the prior year [19] - Adjusted EBITDA for Q4 was -$2.1 million, compared to -$1.4 million in Q4 2024 [19] - Cash and cash equivalents as of December 31, 2025, were $29 million [19] Business Line Data and Key Metrics Changes - Total billable volume in Q4 was approximately 38,000 tests, with tissue-based tests at 11,000 and liquid-based tests at 27,000, representing a total unit growth of 62% year-over-year [16] - Tissue-based test volumes decreased by 5% year-over-year, while liquid-based test volumes increased by 128% [17] Market Data and Key Metrics Changes - The acquisition of ExoDx is expected to significantly contribute to revenue growth, with an anticipated contribution of $20 million or more in 2026 [45] - The company aims to balance revenue growth between tissue and liquid tests, which previously saw tissue tests account for 85% of revenue [45] Company Strategy and Development Direction - MDxHealth is focused on three core operating principles: focus, execution, and growth, which have positioned the company as a leader in precision diagnostics in urology [4][9] - The company is committed to improving the customer experience, achieving a turnaround time of five days or less for critical tissue-based patient samples [8] - The integration of the ExoDx business is expected to enhance operational efficiencies and drive growth [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustained top-line growth while advancing operating profitability, with a target of reaching a 10% EBITDA margin by the end of 2026 [14][20] - The company anticipates some operational challenges in Q4 and Q1 due to the integration of the ExoDx acquisition but expects significant growth opportunities thereafter [32] Other Important Information - The company amended the Exact Sciences earn-out from the GPS acquisition, reducing the upcoming payment by nearly $20 million and deferring the full earn-out amount by an additional year [13] - The collaboration with the University of Oxford is expected to enhance the utility of the GPS test in clinical guidelines, positioning MDxHealth as a leader in risk stratification for prostate cancer [24][25] Q&A Session Summary Question: Tissue ASP decline - The decline in tissue ASP was attributed to a mix shift towards Confirm tests, with no significant issues related to denial rates [30] Question: EBITDA and cash flow concerns - Management acknowledged the lower-than-expected EBITDA and higher cash burn, attributing it to the integration of ExoDx and expressed confidence in future cash flow improvements [31][32] Question: 2026 revenue guidance assumptions - The guidance for 2026 implies 28% growth, driven by core volume growth and contributions from ExoDx, with a focus on balancing growth across tissue and liquid tests [43][45] Question: Operating leverage and gross margin - Management indicated confidence in maintaining flat OpEx while achieving growth, with gross margins expected to remain in the low 60s, aiming for improvements over time [56][60]

Financial Data and Key Metrics Changes - The reported revenue for Q4 2025 was $29.5 million, a 19% increase from $24.7 million in Q4 2024 [11] - Gross profit for Q4 2025 was $18.7 million, up 20% from $15.5 million in Q4 2024, with gross margins increasing to 63.2% from 62.7% [12] - The operating loss for Q4 2025 increased by 14% to $5.3 million compared to $4.6 million in Q4 2024 [12] - The net loss for Q4 2025 rose 31% to $8.9 million from $6.8 million in the prior year [13] - Adjusted EBITDA for Q4 was -$2.1 million, compared to -$1.4 million in Q4 2024 [13] - Cash and cash equivalents as of December 31, 2025, were $29 million [13] Business Line Data and Key Metrics Changes - Total billable volume in Q4 was approximately 38,000 tests, with tissue-based tests decreasing by 5% and liquid-based tests increasing by 128% year-over-year [11] - The acquisition of ExoDx contributed to the growth in liquid-based tests, which include Select mdx, Resolve mdx, and ExoDx [11][36] Market Data and Key Metrics Changes - The company is focused on the urology market, aiming to balance growth between tissue and liquid biopsy products [4][34] - The integration of ExoDx is expected to enhance the company's market position and customer base [36] Company Strategy and Development Direction - MDxHealth's strategy emphasizes focus, execution, and growth, with a commitment to operational discipline and customer experience [3][14] - The company aims to achieve sustained top-line growth while advancing operating profitability, targeting a 10% EBITDA margin by the end of 2026 [9][14] - The integration of ExoDx is a key part of the growth strategy, aimed at enhancing the product offering and customer base [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver growth, citing a disciplined approach to capital allocation and a commitment to patient and customer experience [14][18] - The company anticipates continued growth driven by the integration of ExoDx and the expansion of its diagnostic menu [36][40] Other Important Information - The company amended the Exact Sciences earn-out, reducing the upcoming payment by nearly $20 million and deferring the full amount by an additional year [9] - The collaboration with the University of Oxford is expected to enhance the company's reputation and position in the market [17] Q&A Session Summary Question: Tissue ASP decline and mix shift - Management confirmed that the decline in tissue ASP was due to a mix shift towards Confirm, with ASPs reflecting Medicare rates [20] Question: EBITDA and cash flow concerns - Management acknowledged the lower EBITDA and higher cash flow use, attributing it to the integration of ExoDx and expressed confidence in achieving a 10% EBITDA margin [21][24] Question: 2026 revenue guidance assumptions - Management indicated that the 2026 revenue guidance reflects balanced growth across tissue and liquid products, with expectations of $20 million contribution from ExoDx [35][36] Question: Operating leverage and gross margin expectations - Management stated that they expect to maintain flat OpEx while achieving growth, with gross margins anticipated to remain in the low 60s [44][48]

Core Insights - MDxHealth reported a fourth quarter revenue growth of 19% to $29.5 million and a full-year revenue growth of 20% to $107.9 million, indicating strong commercial execution and operational discipline [1][2][6] - The company anticipates further acceleration in growth for 2026, projecting revenue between $137 million and $140 million, representing a growth rate of 27% to 30% [3][12] Financial Performance - Fourth quarter revenue increased by 19% to $29.5 million compared to $24.7 million in the prior year, with tissue-based tests contributing 59% of total revenue [5][6] - Gross profit for the fourth quarter rose 20% to $18.7 million, with gross margins improving to 63.2% from 62.7% year-over-year [5][9] - Operating expenses increased by 19% to $23.9 million, primarily due to headcount increases and costs related to the ExoDx acquisition [7][10] - The net loss for the fourth quarter was $8.9 million, a 31% increase from $6.8 million in the previous year [7][10] - Adjusted EBITDA for the fourth quarter was ($2.1) million, reflecting a 53% increase compared to ($1.4) million in the same period last year [8][11] Year-End Summary - For the full year 2025, revenue reached $107.9 million, a 20% increase from $90.0 million in 2024, with tissue-based tests accounting for 76% of total revenue [8][10] - Gross profit for the year increased by 26% to $69.6 million, with gross margins improving to 64.5% from 61.2% [9][10] - The net loss for the year decreased by 12% to $33.5 million compared to $38.1 million in 2024, driven by a significant increase in gross profit [10][11] Outlook - The company maintains its 2026 revenue guidance of $137-140 million and aims for an adjusted EBITDA margin of 10% by the end of 2026 [3][12]

Core Insights - MDxHealth SA (NASDAQ:MDXH) is recognized as a fundamentally strong penny stock, particularly following its acquisition of Bio-Techne Corporation's ExoDx business for $15 million, aimed at enhancing its precision diagnostics portfolio [1][2]. Group 1: Acquisition Details - The acquisition agreement was signed on August 5, 2025, with a payment structure that includes $5 million in stock at closing and $2.5 million paid annually over four years, split between cash and stock at the company's discretion [2]. - The ExoDx business includes the ExoDx Prostate test, which is expected to bolster MDxHealth's offerings in precision diagnostics [1]. Group 2: Market Position and Offerings - MDxHealth provides a diverse range of precision diagnostics targeting all stages of prostate cancer and advanced UTI detection, within a market valued at $4.9 billion [3]. - The company offers products such as Select mdx, Confirm mdx, and Resolve mdx, and is committed to improving patient care and healthcare economics [4]. Group 3: Company Background - MDxHealth is headquartered in Herstal, Belgium, and was incorporated in 2003, focusing on commercial-stage precision diagnostics [4]. - The company's strategy includes addressing potential competition while leveraging "sticky adoption" of its products, which is viewed as a positive indicator for future growth [3].

Core Insights - The article discusses fundamentally strong penny stocks that present investment opportunities, emphasizing the combination of high value and low price as a key factor for potential gains [1][2]. Group 1: Penny Stocks Overview - Penny stocks are defined as shares trading under $5, historically showing strong performance and offering opportunities for early investment in emerging companies [2]. - Investors must be discerning to differentiate between good and bad penny stock investments, with strategies that can yield abnormal profits over both short- and long-term periods [3]. Group 2: Methodology for Stock Selection - A list of 12 fundamentally strong penny stocks was compiled, focusing on those with over 5% EPS growth over the past 5 years and positive sales growth, ranked by upside potential based on one-year price targets from Yahoo Finance [5]. Group 3: Company Highlights - **Quipt Home Medical Corp. (NASDAQ:QIPT)**: - Has an upside potential of 31.39% as of September 19, 2025, with a recent acquisition of 150,046 shares by Nuveen LLC valued at approximately $350,000 [7][8]. - The company is expanding through strategic partnerships and a $17.4 million acquisition of Hart Medical Equipment, enhancing revenue stability and future growth opportunities [9][10][11]. - **MDxHealth SA (NASDAQ:MDXH)**: - Shows an upside potential of 45.99% as of September 19, 2025, following the acquisition of Bio-Techne Corporation's ExoDx business for $15 million, aimed at strengthening its precision diagnostics portfolio [12][13][14][15]. - **Butterfly Network, Inc. (NYSE:BFLY)**: - Exhibits an upside potential of 71.35% as of September 19, 2025, with a significant increase in institutional ownership and record quarterly revenue, alongside a bullish outlook from analysts [16][17][18][19].

Core Insights - MDxHealth reported a year-over-year revenue increase of 22% to $24.3 million for Q1 2025, marking the 16th consecutive quarter of revenue growth of 20% or more [1][2][6] - The company expects to achieve adjusted EBITDA profitability in Q2 2025 and has reiterated its revenue guidance for 2025 at $108-110 million [2][9] Financial Performance - Revenue for Q1 2025 was $24.3 million, up from $19.8 million in Q1 2024, representing a 22% increase [4][6] - Gross profit increased by 29% to $15.5 million, with gross margins improving to 63.8% from 60.8% year-over-year [7][9] - Operating expenses rose by 8% to $20.1 million, primarily due to increased clinical trial expenses and stock-based compensation [7][9] - The net loss for Q1 2025 was $9.2 million, an 8% increase from $8.5 million in the prior year, largely due to non-cash fair value adjustments [8][9] - Adjusted EBITDA improved by 71% to a loss of $1.3 million compared to a loss of $4.5 million in Q1 2024 [10][23] Operational Highlights - Tissue-based tests accounted for 85% of total revenue in Q1 2025, up from 79% in Q1 2024 [6] - Test volumes for tissue-based tests increased by 41% to 12,677, while liquid-based test volumes rose by 9% to 11,530 [9] - The company ended Q1 2025 with cash and cash equivalents of $65.7 million [10][22] Subsequent Events - On April 29, 2025, MDxHealth made a $28.0 million earnout payment to Exact Sciences, which would adjust the pro-forma cash balance to $37.7 million as of March 31, 2025 [11]

Financial Data and Key Metrics Changes - The company reported a 28% revenue growth for Q4 2024, reaching $24.7 million compared to $19.4 million in Q4 2023 [16] - Gross profit for Q4 2024 was $15.5 million, a 22% increase from $12.7 million in Q4 2023, with gross margins at 62.7% [17] - The operating loss decreased by 27% to $4.6 million, while the net loss decreased by 36% to $6.8 million [18][19] - Adjusted EBITDA improved by 68% to negative $1.4 million from negative $4.4 million in Q4 2023 [20] Business Line Data and Key Metrics Changes - Total billable volume for Q4 was approximately 24,000 tests, a 26% increase [8] - Tissue-based tests, including Confirm mdx and GPS, saw a 50% increase year-over-year, totaling almost 12,000 tests in Q4 [9] - Liquid-based tests, including Select mdx, Resolve mdx, and Germline, exceeded 12,000 tests, marking a 10% increase year-over-year [9] Market Data and Key Metrics Changes - The urology diagnostic market is expected to grow at an annual rate of 5% to 10% due to factors such as increasing prostate cancer rates and an aging population [25] - The company is positioned uniquely in the market, providing clinically actionable results after initial biopsy, which is expected to drive further growth [11] Company Strategy and Development Direction - The company aims to achieve a revenue guidance of $108 million to $110 million for 2025, maintaining a goal of 20% revenue growth [14] - The focus remains on execution and leveraging existing sales channels without expanding the sales organization [12][24] - The company emphasizes building a trusted brand in the urology market through high-quality service and customer support [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive adjusted EBITDA in the first half of 2025 [20][84] - The company is optimistic about the adoption of its tests and the overall growth trajectory, despite challenges in the diagnostic pathway for patients [12][66] - Management noted that the NCCN guidelines created confusion but did not negatively impact growth, as evidenced by accelerating test volumes [44] Other Important Information - Cash and cash equivalents as of December 31, 2024, were $46.8 million, with plans to strengthen the balance sheet through a pending draw from the OrbiMed debt facility [21] - The company has a structured plan for the Germline test, expecting it to contribute to growth in 2025, albeit conservatively [31] Q&A Session Summary Question: Contribution of Germline to 2025 growth - Management is confident that Germline will contribute to growth in 2025, following a conservative approach similar to the Resolve test [31] Question: Outlook on gross margins - Management does not provide specific guidance on gross margins but expects them to remain in the mid-60s for the next few quarters [34] Question: OpEx outlook and adjusted EBITDA - Management indicated that the growth strategy remains unchanged, with no significant changes in OpEx expected as the business begins to fund itself [40][41] Question: Impact of NCCN guidelines on business - Management noted that the NCCN guidelines created confusion but did not negatively impact growth, with strong channel checks supporting their position [44] Question: Test menu breadth and new additions - Management believes the current test menu is sufficient to meet growth objectives, with no immediate plans for new test additions in 2025 [51][54] Question: Impact of Medicare reimbursement on commercial coverage - Management reported solid growth across the test menu, with expectations for continued expansion of coverage with commercial and private payers [57] Question: Timing of Exact Sciences earn-out payments - The earn-out payments to Exact Sciences are expected to occur in Q2 each year for 2025, 2026, and 2027 [88]